Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate; and AbbVie Inc. to develop and commercialize products containing duvelisib in oncology indications., as well as collaboration agreements with Arcus Biosciences, Inc. and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INFI
Previous Symbol
CUSIP45665G30
Phone617-453-1000
Debt
Debt-to-Equity RatioN/A
Current Ratio10.68
Quick Ratio10.68
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$6 million
Price / Sales11.56
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.94 per share
Price / Book1.30
Profitability
EPS (Most Recent Fiscal Year)($0.83)
Net Income$-41,830,000.00
Net MarginsN/A
Return on Equity-20.82%
Return on Assets-18.24%
Miscellaneous
Employees22
Outstanding Shares56,870,000
Market Cap$69.38 million
OptionableOptionable
Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions
What is Infinity Pharmaceuticals' stock symbol?
Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."
How were Infinity Pharmaceuticals' earnings last quarter?
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) issued its quarterly earnings data on Monday, November, 5th. The biotechnology company reported $0.23 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.14) by $0.37. The biotechnology company earned $22 million during the quarter. View Infinity Pharmaceuticals' Earnings History.
When is Infinity Pharmaceuticals' next earnings date?
What price target have analysts set for INFI?
3 analysts have issued 12 month price objectives for Infinity Pharmaceuticals' shares. Their predictions range from $4.00 to $4.00. On average, they expect Infinity Pharmaceuticals' share price to reach $4.00 in the next year. This suggests a possible upside of 227.9% from the stock's current price. View Analyst Price Targets for Infinity Pharmaceuticals.
What is the consensus analysts' recommendation for Infinity Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Infinity Pharmaceuticals.
Has Infinity Pharmaceuticals been receiving favorable news coverage?
News headlines about INFI stock have been trending very positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Infinity Pharmaceuticals earned a daily sentiment score of 3.2 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days.
Are investors shorting Infinity Pharmaceuticals?
Infinity Pharmaceuticals saw a increase in short interest in November. As of November 30th, there was short interest totalling 1,460,223 shares, an increase of 34.3% from the November 15th total of 1,087,410 shares. Based on an average daily trading volume, of 604,792 shares, the days-to-cover ratio is currently 2.4 days. Approximately 2.7% of the shares of the company are sold short. View Infinity Pharmaceuticals' Current Options Chain.
Who are some of Infinity Pharmaceuticals' key competitors?
Some companies that are related to Infinity Pharmaceuticals include MannKind (MNKD), Merus (MRUS), Athersys (ATHX), BIOFRONTERA AG/ADR (BFRA), Verrica Pharmaceuticals (VRCA), Intec Pharma (NTEC), Kadmon (KDMN), Savara (SVRA), Adamas Pharmaceuticals (ADMS), Geron (GERN), BioDelivery Sciences International (BDSI), Magenta Therapeutics (MGTA), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO) and Arbutus Biopharma (ABUS).
Who are Infinity Pharmaceuticals' key executives?
Infinity Pharmaceuticals' management team includes the folowing people:
- Ms. Adelene Q. Perkins, Chairman & CEO (Age 58)
- Dr. Lawrence E. Bloch, Pres & Treasurer (Age 52)
- Dr. Jeffery L. Kutok, Sr. VP & Chief Scientific Officer (Age 51)
- Mr. Seth A. Tasker, VP, Gen. Counsel & Sec. (Age 39)
- Ms. Melissa Hackel, VP of Fin.
Who are Infinity Pharmaceuticals' major shareholders?
Infinity Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (1.87%), Platinum Investment Management Ltd. (1.74%), Renaissance Technologies LLC (1.30%), Northpointe Capital LLC (0.93%), EcoR1 Capital LLC (0.81%) and Essex Investment Management Co. LLC (0.64%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Bvf Partners L P/Il, Jeffery Kutok, Lawrence E Bloch, Michael C Venuti and Value Fund L P Biotechnology. View Institutional Ownership Trends for Infinity Pharmaceuticals.
Which major investors are selling Infinity Pharmaceuticals stock?
INFI stock was sold by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd. and Wells Fargo & Company MN. Company insiders that have sold Infinity Pharmaceuticals company stock in the last year include Adelene Q Perkins and Jeffery Kutok. View Insider Buying and Selling for Infinity Pharmaceuticals.
Which major investors are buying Infinity Pharmaceuticals stock?
INFI stock was bought by a variety of institutional investors in the last quarter, including Northpointe Capital LLC, Fosun International Ltd, Opaleye Management Inc., Essex Investment Management Co. LLC, Renaissance Technologies LLC, Dimensional Fund Advisors LP and EcoR1 Capital LLC. Company insiders that have bought Infinity Pharmaceuticals stock in the last two years include Bvf Partners L P/Il, Lawrence E Bloch and Value Fund L P Biotechnology. View Insider Buying and Selling for Infinity Pharmaceuticals.
How do I buy shares of Infinity Pharmaceuticals?
Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Infinity Pharmaceuticals' stock price today?
One share of INFI stock can currently be purchased for approximately $1.22.
How big of a company is Infinity Pharmaceuticals?
Infinity Pharmaceuticals has a market capitalization of $68.24 million and generates $6 million in revenue each year. The biotechnology company earns $-41,830,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Infinity Pharmaceuticals employs 22 workers across the globe.
What is Infinity Pharmaceuticals' official website?
How can I contact Infinity Pharmaceuticals?
Infinity Pharmaceuticals' mailing address is 784 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]
MarketBeat Community Rating for Infinity Pharmaceuticals (NASDAQ INFI)
MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote "Outperform" if you believe INFI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INFI will underperform the S&P 500 over the long term. You may vote once every thirty days.
